GoodRx released its new Weight Loss Medications Tracker, revealing that Americans overspent by at least $200 million in 2024 on popular weight loss medications by not utilizing available savings options. This highlights a significant market opportunity for GoodRx's platform.
The data showed prescription fills for Wegovy and Zepbound more than doubled and tripled, respectively, since the start of 2024, despite limited insurance coverage and high out-of-pocket costs. This surge indicates strong consumer demand for these medications.
GoodRx's research found that patients can save an average of $250 per month, or $3,000 annually, on commonly prescribed GLP-1 and GIP medications using its coupons. This underscores the platform's ability to provide substantial financial relief in a high-cost therapeutic area.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.